{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:08:29Z","timestamp":1790096909419,"version":"4.0.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drudis.2026.104777","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:30:07Z","timestamp":1787095807000},"page":"104777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paediatric Regulation in the European Union: an overview"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4379-5524","authenticated-orcid":false,"given":"Paolo","family":"Caferra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fraisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Baffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kalfon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Trincavelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Piras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104777_b0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.phrs.2011.01.016","article-title":"The development of medicines for children","volume":"64","author":"Rocchi","year":"2011","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2026.104777_b0010","doi-asserted-by":"crossref","first-page":"F142","DOI":"10.1136\/fn.80.2.F142","article-title":"Unlicensed and off label drug use in neonates commentary","volume":"80","author":"Conroy","year":"1999","journal-title":"Arch Dis Child \u2013 Fetal Neonatal Ed"},{"key":"10.1016\/j.drudis.2026.104777_b0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00228-005-0894-9","article-title":"Clinical trials of medication in children, 1996\u20132002","volume":"61","author":"Sammons","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104777_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002018-200225010-00001","article-title":"Unlicensed and off-label drug use in children: implications for safety","volume":"25","author":"Choonara","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.drudis.2026.104777_b0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/bmj.320.7227.79","article-title":"Survey of unlicensed and off label drug use in paediatric wards in European countries","volume":"320","author":"Conroy","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2026.104777_b0030","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/archpedi.161.3.282","article-title":"Off-label drug use in hospitalized children","volume":"161","author":"Shah","year":"2007","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.drudis.2026.104777_b0035","unstructured":"European Parliament and Council. REGULATION (EC) No 1901\/2006 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 12 December 2006 on Medicinal Products for Paediatric Use and Amending Regulation (EEC) No 1768\/92, Directive 2001\/20\/EC, Directive 2001\/83\/EC and Regulation (EC) No 726\/2004. 2006. Accessed 9 Jan 2025. https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2006:378:0001:0019:en:PDF."},{"key":"10.1016\/j.drudis.2026.104777_b0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.12793\/tcp.2018.26.4.155","article-title":"Regulatory innovation for expansion of indications and pediatric drug development","volume":"26","author":"Park","year":"2018","journal-title":"Transl Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104777_b0045","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00228-011-0997-4","article-title":"Three years of paediatric regulation in the European Union","volume":"67","author":"Olski","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104777_b0050","unstructured":"European Medicines Agency. 10-Year Report to the European Commission \u2013 General Report on the Experience Acquired as a Result of the Application of the Paediatric Regulation. 2017. Accessed 1 Sep 2024. https:\/\/health.ec.europa.eu\/document\/download\/cf6bdf31-ecb4-4376-9fb3-c5146e41d079_en."},{"key":"10.1016\/j.drudis.2026.104777_b0055","unstructured":"European Parliament and Council. REGULATION (EC) No 1902\/2006 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 20 December 2006 Amending Regulation 1901\/2006 on Medicinal Products for Paediatric Use. 2006. Accessed 13 Sep 2024. http:\/\/data.europa.eu\/eli\/reg\/2006\/1902\/oj."},{"key":"10.1016\/j.drudis.2026.104777_b0060","series-title":"Handbook of the Philosophy of Medicine","first-page":"1","article-title":"Children are not small adults: significance of biological and cognitive development in medical practice","author":"Larcher","year":"2015"},{"key":"10.1016\/j.drudis.2026.104777_b0065","series-title":"Drug Development \u2013 A Case Study Based Insight into Modern Strategies","article-title":"Changes in research and development of medicinal products since the paediatric regulation","author":"Ceci","year":"2011"},{"key":"10.1016\/j.drudis.2026.104777_b0070","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00431-013-2096-2","article-title":"Who are the PDCO?","volume":"173","author":"Dempsey","year":"2014","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.drudis.2026.104777_b0075","unstructured":"European Medicines Agency. PDCO members. Accessed 5 Jul 2026. https:\/\/www.ema.europa.eu\/en\/committees\/paediatric-committee-pdco\/pdco-members."},{"key":"10.1016\/j.drudis.2026.104777_b0500","unstructured":"European Commission. Medicines for children. Medicines for children. Accessed 29 Jul 2026. https:\/\/health.ec.europa.eu\/medicinal-products\/product-types\/medicines-children_en#the-2017-paediatric-report."},{"key":"10.1016\/j.drudis.2026.104777_b0085","unstructured":"European Medicines Agency. Questions and answers on the procedure of PIP compliance verification at EMA, and on paediatric rewards (revised December 2014). Published online December 15, 2014. Accessed 9 Jan 2025. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/questions-and-answers-procedure-paediatric-investigation-plan-compliance-verification-european-medicines-agency-and-paediatric-rewards_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0080","unstructured":"European Commission. Medicines for children. Accessed 6 Jun 2025. https:\/\/health.ec.europa.eu\/medicinal-products\/medicines-children_en#annual-reports."},{"key":"10.1016\/j.drudis.2026.104777_b0090","first-page":"1157","article-title":"Developmental pharmacology \u2014 drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003"},{"key":"10.1016\/j.drudis.2026.104777_b0095","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/ajhp\/zxz171","article-title":"Pharmacy and pediatric drug therapy: the key to safe and effective treatment for children","volume":"76","author":"Rieder","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.drudis.2026.104777_b0100","unstructured":"European Commission. Communication from the Commission \u2013 Guideline on the format and content of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals and concerning the operation of the compliance check and on criteria for assessing significant studies. Published online 27 Sep 2014. Accessed 22 Sep 2024. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:52014XC0927(01)."},{"key":"10.1016\/j.drudis.2026.104777_b0105","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jbi.2014.03.012","article-title":"Formalizing MedDRA to support semantic reasoning on adverse drug reaction terms","volume":"49","author":"Bousquet","year":"2014","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.drudis.2026.104777_b0110","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/bcp.12402","article-title":"Bridging the gap: a review of dose investigations in paediatric investigation plans","volume":"78","author":"Hampson","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104777_b0115","unstructured":"European Medicines Agency. Examples of key binding elements in the PIP decisions. Published online 16 Dec 2013. Accessed 13 May 2026. https:\/\/www.ema.europa.eu\/en\/documents\/other\/examples-key-binding-elements-paediatric-investigation-plan-decisions_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0120","unstructured":"European Medicines Agency. Tivicay-H-C-2753-X-0058-G: EPAR \u2013 Assessment Report \u2013 Variation. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/tivicay-h-c-2753-x-0058-g-epar-assessment-report-variation_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0125","article-title":"Oral medicines for children in the European Paediatric Investigation Plans","volume":"9","author":"Van Riet-Nales","year":"2014"},{"key":"10.1016\/j.drudis.2026.104777_b0130","unstructured":"European Medicines Agency. Inovelon-H-C-660-X-17\u00a0: EPAR \u2013 Assessment Report \u2013 Extension. 2012. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/inovelon-h-c-660-x-17-epar-assessment-report-extension_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0135","unstructured":"European Medicines Agency. Tuzulby\u00a0: EPAR \u2013 Public Assessment Report. 2024. Accessed 18 Jul 2026. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/tuzulby-epar-public-assessment-report_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0140","unstructured":"European Medicines Agency. Fluenz\u00a0: EPAR \u2013 Public Assessment Report. 2024. Accessed 18 Jul 2026. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/fluenz-epar-public-assessment-report_en.pdf-0."},{"key":"10.1016\/j.drudis.2026.104777_b0145","unstructured":"European Medicines Agency. Triumeq\u00a0: EPAR \u2013 Public Assessment Report. 2014. Accessed 18 Jul 2026. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/triumeq-epar-public-assessment-report_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0150","unstructured":"European Medicines Agency. Final paediatric investigation plan: Expected key elements and requirements for a new DTaP-containing combination vaccine for primary and booster vaccination in infants and toddlers. Published online 13 Oct 2015. Accessed 12 Sep 2024. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/final-paediatric-investigation-plan-expected-key-elements-and-requirements-new-dtap-containing-combination-vaccine-primary-and-booster-vaccination-infants-and-toddlers_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0155","unstructured":"European Council. Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulation (EC) No 1394\/2007 and Regulation (EU) No 536\/2014 and repealing Regulation (EC) No 726\/2004, Regulation (EC) No 141\/2000 and Regulation (EC) No 1901\/2006. Published online 24 Feb 2026. Accessed 12 Jun 2026. https:\/\/data.consilium.europa.eu\/doc\/document\/ST-6366-2026-INIT\/en\/pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0160","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa067597","article-title":"Natural history of multiple sclerosis with childhood onset","volume":"356","author":"Renoux","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104777_b0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12883-018-1026-3","article-title":"Pediatric multiple sclerosis: a review","volume":"18","author":"Alroughani","year":"2018","journal-title":"BMC Neurol"},{"key":"10.1016\/j.drudis.2026.104777_b0170","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/2168479016646809","article-title":"A comparative review of waivers granted in pediatric drug development by FDA and EMA from 2007\u20132013","volume":"50","author":"Egger","year":"2016","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.drudis.2026.104777_b0175","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40272-017-0261-1","article-title":"Enabling development of paediatric medicines in Europe: 10 years of the EU paediatric regulation","volume":"19","author":"Tomasi","year":"2017","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.drudis.2026.104777_b0180","unstructured":"European Medicines Agency. On the refusal of a paediatric investigation plan and on the granting of a waiver for dupilumab (Dupixent), (EMEA-001501-PIP08-20) in accordance with Regulation (EC) No 1901\/2006 of the European Parliament and of the Council. Published online 17 Mar 2021. Accessed 12 Apr 2026. https:\/\/www.ema.europa.eu\/en\/documents\/pip-decision\/p-0121-2021-ema-decision-17-march-2021-refusal-paediatric-investigation-plan-granting-waiver-dupilumab-dupixent-emea-001501-pip08-20_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0185","unstructured":"European Medicines Agency. European Medicines Agency decision CW\/0001\/2015 of 23 July 2015 on class waivers, in accordance with Regulation (EC) No 1901\/2006 of the European Parliament and of the Council. Published online 23 Jul 2015. Accessed 12 Sep 2024. https:\/\/www.ema.europa.eu\/en\/documents\/other\/european-medicines-agency-decision-cw-0001-2015-23-july-2015-class-waivers-accordance-regulation-ec-no-1901-2006-european-parliament-and-council_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0190","unstructured":"European Medicines Agency. \u201cSignificant Benefit\u201d across provisions. December 3, 2018. Accessed 19 Sep 2024. https:\/\/health.ec.europa.eu\/system\/files\/2019-01\/stamp_10_co05_en_0.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0195","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.2147\/DDDT.S378813","article-title":"Scientific rationale for waiving clinical efficacy testing of biosimilars","volume":"16","author":"Niazi","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.drudis.2026.104777_b0200","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/ijms20010213","article-title":"Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties","volume":"20","author":"Kawauchi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104777_b0205","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s40521-019-00222-1","article-title":"The Explosion of OTC management of allergic rhinitis: costs and risks","volume":"6","author":"Ivancevich","year":"2019","journal-title":"Curr Treat Options Allergy"},{"key":"10.1016\/j.drudis.2026.104777_b0210","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3390\/ijerph15102232","article-title":"Management of pediatric febrile seizures","volume":"15","author":"Laino","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.drudis.2026.104777_b0215","first-page":"5","article-title":"Febrile seizures: four steps algorithmic clinical approach","volume":"20","author":"Mohammadi","year":"2010","journal-title":"Iran J Pediatr"},{"key":"10.1016\/j.drudis.2026.104777_b0220","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/pr.2018.38","article-title":"Useful pharmacodynamic endpoints in children: selection, measurement, and next steps","volume":"83","author":"Kelly","year":"2018","journal-title":"Pediatr Res"},{"key":"10.1016\/j.drudis.2026.104777_b0225","unstructured":"European Commission. Ethical considerations for clinical trials on medicinal products conducted with minors \u2013 Recommendations of the expert group on clinical trials for the implementation of Regulation (EU) No 536\/2014 on clinical trials on medicinal products for human use. Published online 18 Sep 2017. Accessed 19 Sep 2024. https:\/\/health.ec.europa.eu\/system\/files\/2018-02\/2017_09_18_ethical_consid_ct_with_minors_0.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0230","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cpt.142","article-title":"Failed Pediatric Drug Development Trials","volume":"98","author":"Momper","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104777_b0235","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/21678421.2021.2024856","article-title":"Clinical trials in pediatric ALS: a TRICALS feasibility study","volume":"23","author":"Kliest","year":"2022","journal-title":"Amyotroph Lateral Scler Front Degener"},{"key":"10.1016\/j.drudis.2026.104777_b0240","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s13063-016-1415-0","article-title":"Identifying the participant characteristics that predict recruitment and retention of participants to randomised controlled trials involving children: a systematic review","volume":"17","author":"Robinson","year":"2016","journal-title":"Trials"},{"key":"10.1016\/j.drudis.2026.104777_b0245","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41390-023-02465-w","article-title":"Barriers to enrollment in a pediatric critical care biorepository","volume":"94","author":"Paquette","year":"2023","journal-title":"Pediatr Res"},{"key":"10.1016\/j.drudis.2026.104777_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1009432","article-title":"Mandatory requirements for pediatric drug development in the EU and the US for novel drugs \u2013 a comparative study","volume":"9","author":"Christiansen","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.drudis.2026.104777_b0255","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S2352-4642(22)00344-3","article-title":"Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents","volume":"7","author":"Vassal","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.drudis.2026.104777_b0260","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1016\/S1470-2045(17)30442-4","article-title":"From class waivers to precision medicine in paediatric oncology","volume":"18","author":"Pearson","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2026.104777_b0265","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/cpt.2152","article-title":"Optimizing pediatric medicine developments in the European Union through pragmatic approaches","volume":"110","author":"Rei Bolislis","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104777_b0270","unstructured":"European Council. Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on the Union code relating to medicinal products for human use, and repealing Directive 2001\/83\/EC and Directive 2009\/35\/EC. Published online 24 Feb 2026. Accessed 19 Apr 2026. https:\/\/data.consilium.europa.eu\/doc\/document\/ST-6367-2026-INIT\/en\/pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0275","unstructured":"European Parliamentary Research Service, Izabela Bacian. Revision of the EU legislation on medicines for children and rare diseases. Published online Jun 2023. Accessed 9 Jan 2025. https:\/\/www.europarl.europa.eu\/RegData\/etudes\/BRIE\/2023\/747440\/EPRS_BRI(2023)747440_EN.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0280","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1179\/2047480612Z.00000000021","article-title":"Writing applications for Paediatric Investigation Plans and waivers","volume":"21","author":"Tomasi","year":"2012","journal-title":"Med Writ"},{"key":"10.1016\/j.drudis.2026.104777_b0285","unstructured":"European Medicines Agency. Policy on the determination of the condition(s) for a Paediatric Investigation Plan\/Waiver (scope of the PIP\/waiver). Published online 15 Jan 2024. Accessed 12 Apr 2026. https:\/\/www.ema.europa.eu\/en\/documents\/other\/policy-determination-conditions-paediatric-investigation-plan-pip-waiver-scope-pip-waiver_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0290","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2022.09.025","article-title":"European regulatory strategy for supporting childhood cancer therapy developments","volume":"177","author":"Karres","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.drudis.2026.104777_b0295","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.3390\/jcm14175994","article-title":"Utilization of child-appropriate medicines: use of Pediatric Use Marketing Authorisation (PUMA) products in Croatia","volume":"14","author":"Belan\u010di\u0107","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.drudis.2026.104777_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.593281","article-title":"Paediatric medicines in Europe: the paediatric regulation \u2013 is it time for reform?","volume":"8","author":"Toma","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.drudis.2026.104777_b0305","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/2168479014537260","article-title":"The first paediatric use marketing authorisation: a case study","volume":"49","author":"Watson","year":"2015","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.drudis.2026.104777_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104286","article-title":"Revising EU pharmaceutical legislation: will it foster drug repurposing?","volume":"30","author":"Scholte","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104777_b0315","series-title":"Study on the Economic Impact of the Paediatric Regulation, Including Its Rewards and Incentives","author":"Varnai","year":"2016"},{"key":"10.1016\/j.drudis.2026.104777_b0320","unstructured":"European Commission. Supplementary protection certificates for pharmaceutical and plant protection products. Accessed 9 Jan 2025. https:\/\/single-market-economy.ec.europa.eu\/industry\/strategy\/intellectual-property\/patent-protection-eu\/supplementary-protection-certificates-pharmaceutical-and-plant-protection-products_en."},{"key":"10.1016\/j.drudis.2026.104777_b0325","unstructured":"European Parliament and Council. REGULATION (EC) No 469\/2009 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 May 2009 Concerning the Supplementary Protection Certificate for Medicinal Products. Accessed 8 Sep 2024. https:\/\/eur-lex.europa.eu\/legal-content\/TR\/TXT\/?uri=celex%3A32009R0469."},{"key":"10.1016\/j.drudis.2026.104777_b0330","unstructured":"European Commission. Commission Report On The Paediatric Regulation (Article 50(3) Of Regulation (Ec) No 1901\/2006). Published online 14 Nov 2016. Accessed 8 Sep 2024. https:\/\/health.ec.europa.eu\/document\/download\/7a12eca1-7903-4ada-8b7a-653d6f02f835_en."},{"key":"10.1016\/j.drudis.2026.104777_b0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40545-019-0198-6","article-title":"Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib","volume":"13","author":"Hu","year":"2020","journal-title":"J Pharm Policy Pract"},{"key":"10.1016\/j.drudis.2026.104777_b0340","unstructured":"European Parliament and Council. Regulation (EC) No 726\/2004 of the European Parliament and of the Council of 31 March 2004 Laying down Community Procedures for the Authorisation and Supervision of Medicinal Products for Human and Veterinary Use and Establishing a European Medicines Agency. Accessed 3 Dec 2024. http:\/\/data.europa.eu\/eli\/reg\/2004\/726\/oj."},{"key":"10.1016\/j.drudis.2026.104777_b0345","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/archdischild-2015-309519","article-title":"Usage of unpublished paediatric data","volume":"101","author":"Saint-Raymond","year":"2016","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.drudis.2026.104777_b0350","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1574886313666180619120406","article-title":"Off-label use of drugs and adverse drug reactions in pediatric units: a prospective, multicenter study","volume":"13","author":"Pratico","year":"2018","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.drudis.2026.104777_b0355","series-title":"Drug Discovery and Development \u2013 From Molecules to Medicine","article-title":"Clinical trials in paediatrics \u2013 regulatory and methodological aspects","author":"Ceci","year":"2015"},{"key":"10.1016\/j.drudis.2026.104777_b0360","article-title":"Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: a cohort study","volume":"15","author":"Hwang","year":"2018"},{"key":"10.1016\/j.drudis.2026.104777_b0365","unstructured":"European Medicines Agency. Concept paper on the development of a reflection paper on proof-of-concept data to support the development of anti-cancer medicinal products in paediatric patients. Published online 16 Feb 2026. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/concept-paper-development-reflection-paper-proof-concept-data-support-development-anti-cancer-medicinal-products-paediatric-patients_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0370","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13023-014-0120-x","article-title":"The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children","volume":"9","author":"Kreeftmeijer-Vegter","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2026.104777_b0375","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3390\/pharmaceutics12121176","article-title":"Cardiovascular paediatric medicines development: have paediatric investigation plans lost heart?","volume":"12","author":"Faulkner","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104777_b0380","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/ecp.11.43","article-title":"Innovative clinical trial design for pediatric therapeutics","volume":"4","author":"Laughon","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104777_b0385","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/pharmaceutics3010053","article-title":"Factors and mechanisms for pharmacokinetic differences between pediatric population and adults","volume":"3","author":"Fernandez","year":"2011","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104777_b0390","unstructured":"European Medicines Agency. Lyxumia\u00a0: EPAR \u2013 Product Information. Accessed 8 Sep 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lyxumia-epar-product-information_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0395","unstructured":"European Medicines Agency. Zoely: EPAR \u2013 Product Information. Accessed 8 Sep 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zoely-epar-product-information_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0400","unstructured":"European Medicines Agency. Public summary of opinion on orphan designation (3S)-1-azabicyclo[2.2.2]oct-3-yl{2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate for the treatment of Fabry disease. Published online 22 Aug 2014. Accessed 1 May 2026. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu3141310-public-summary-opinion-orphan-designation-3s-1-azabicyclo222oct-3-yl2-2-4-fluorophenyl-13-thiazol-4-ylpropan-2-ylcarbamate-treatment-fabry-disease_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0405","unstructured":"European Medicines Agency. Public summary of opinion on orphan designation (3S)-1-azabicyclo[2.2.2]oct-3-yl{2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate for the treatment of Gaucher disease. Published online 19 Nov 2014. Accessed 1 May 2026. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu3141374-public-summary-opinion-orphan-designation-3s-1-azabicyclo222oct-3-yl2-2-4-fluorophenyl-13-thiazol-4-ylpropan-2-ylcarbamate-treatment-gaucher-disease_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0410","unstructured":"European Medicines Agency. P\/0385\/2024: EMA decision of 25 October 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for venglustat (EMEA-001716-PIP08-23). Published online 25 Oct 2024. Accessed 1 May 2026. https:\/\/www.ema.europa.eu\/en\/documents\/pip-decision\/p-0385-2024-ema-decision-25-october-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-venglustat-emea-001716-pip08-23_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0415","unstructured":"European Medicines Agency. P\/0172\/2024: EMA decision of 3 May 2024 on the acceptance of a modification of an agreed paediatric investigation plan for venglustat (EMEA- 001716-PIP07-22-M01). Published online 3 May 2024. Accessed 14 Mar 2026. https:\/\/www.ema.europa.eu\/en\/documents\/pip-decision\/p-0172-2024-ema-decision-3-may-2024-acceptance-modification-agreed-paediatric-investigation-plan-venglustat-emea-001716-pip07-22-m01_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0420","unstructured":"European Medicines Agency. European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). Accessed 3 May 2026. https:\/\/www.ema.europa.eu\/en\/partners-networks\/networks\/european-network-paediatric-research-european-medicines-agency-enpr-ema#also-on-this-topic-63025."},{"key":"10.1016\/j.drudis.2026.104777_b0425","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3846\/1392-8619.2008.14.144-150","article-title":"\u201cInstitutional capital\u201d as a factor of sustainable development \u2013 the importance of an institutional equilibrium\/Institucinis kapitalas kaip darnaus vystymosi veiksnys \u2013 institucin\u0117s pusiausvyros svarba","volume":"14","author":"Platje","year":"2008","journal-title":"Technol Econ Dev Econ"},{"key":"10.1016\/j.drudis.2026.104777_b0430","unstructured":"European Medicines Agency. Guidance for stepwise PIPs (sPIPs). Published online 17 Nov 2025. Accessed 12 Apr 2026. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guidance-stepwise-pips-spips_en.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0435","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S1470-2045(15)00202-8","article-title":"EMA paediatric medicine waivers","volume":"16","author":"Burki","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2026.104777_b0440","series-title":"The Management of Clinical Trials","article-title":"Challenges in paediatric clinical trials: how to make it feasible","author":"Chiaruttini","year":"2018"},{"key":"10.1016\/j.drudis.2026.104777_b0445","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1586\/ecp.09.40","article-title":"Challenges in conducting clinical trials in children: approaches for improving performance","volume":"2","author":"Kern","year":"2009","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104777_b0450","unstructured":"European Council. \u2018Pharma package\u2019: Council and Parliament reach a deal on new rules for a fairer and more competitive EU pharmaceutical sector. Accessed 31 Dec 2025. https:\/\/www.consilium.europa.eu\/en\/press\/press-releases\/2025\/12\/11\/pharma-package-council-and-parliament-reach-a-deal-on-new-rules-for-a-fairer-and-more-competitive-eu-pharmaceutical-sector\/."},{"key":"10.1016\/j.drudis.2026.104777_b0455","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13023-017-0676-3","article-title":"European Reference networks for rare diseases: what is the conceptual framework?","volume":"12","author":"H\u00e9on-Klin","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2026.104777_b0460","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2024.1388170","article-title":"Partnership of I-ACT for children (US) and European pediatric clinical trial networks to facilitate pediatric clinical trials","volume":"12","author":"Degraeuwe","year":"2024","journal-title":"Front Pediatr"},{"key":"10.1016\/j.drudis.2026.104777_b0465","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1553448","article-title":"Advancing European paediatric research \u2013 the contribution of the Innovative Health Initiative","volume":"12","author":"Seigneuret","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.drudis.2026.104777_b0470","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1136\/archdischild-2020-321433","article-title":"Recommendations by the European Network of Paediatric Research at the European Medicines Agency (ENPR-EMA) Working Group on preparedness of clinical trials about paediatric medicines process","volume":"106","author":"Siapkara","year":"2021","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.drudis.2026.104777_b0475","article-title":"Paediatric formulations \u2013 part of the repurposing concept?","volume":"11","author":"Wang","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.drudis.2026.104777_b0480","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1473862","article-title":"Effects of the Paediatric Regulation funding on the development of off-patent medicines in children","volume":"11","author":"Ruggieri","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.drudis.2026.104777_b0485","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.746987","article-title":"Drug repurposing for rare diseases: a role for academia","volume":"12","author":"Van Den Berg","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104777_b0490","unstructured":"Working group of the Safe and Timely Access to Medicines for Patients (STAMP) expert group. Proposal for a framework to support not-for-profit organisations and academia (institutions and individuals) in drug repurposing. Published online Jun 2019. Accessed 4 Dec 2024. https:\/\/health.ec.europa.eu\/system\/files\/2021-10\/pharm773_repurposing_annex_en_0.pdf."},{"key":"10.1016\/j.drudis.2026.104777_b0495","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1375988","article-title":"Reflections on the regulatory field covering the development of paediatric medicinal products: a brief overview of current status and challenges","volume":"15","author":"Lehmann","year":"2024","journal-title":"Front Pharmacol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:20:02Z","timestamp":1790094002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1359644626001820"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104777","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paediatric Regulation in the European Union: an overview","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104777"}}